Loading
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Latest quote
$11.57
−$0.52 · -4.30%
After-hours
$11.74
+$0.17 · +1.47%
Sep 10, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Day range
Current $11.57
52-week range
Current $11.57
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
88
Deep Value
Sentiment
53
Mixed
Risk
39
Moderate Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Day range
Current $11.57
52-week range
Current $11.57
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 67.48M USD | 53.88M USD | — | — | — |
| Cost of goods sold | 57K USD | — | 849K USD | — | — |
| Gross profit | 67.43M USD | 53.88M USD | −849K USD | — | — |
| Research and development | 251.07M USD | 169.97M USD | 115.24M USD | 92.81M USD | 84.72M USD |
| Selling, general, and administrative | 119.98M USD | 77.11M USD | 50.57M USD | 47.05M USD | 46.54M USD |
| Operating expenses | 371.06M USD | 247.08M USD | 164.96M USD | 139.87M USD | 131.26M USD |
| Interest income | 26.77M USD | 22.85M USD | 14.72M USD | 4.25M USD | 1.21M USD |
| Interest expense | 1.51M USD | 1.62M USD | 1.55M USD | 229K USD | 414K USD |
| Depreciation and amortization | 1.03M USD | 848K USD | 849K USD | 759K USD | 558K USD |
| Operating income | −303.63M USD | −193.2M USD | −165.8M USD | −139.87M USD | −131.26M USD |
| Net income | −278.67M USD | −173.98M USD | −152.63M USD | −135.84M USD | −130.47M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$22.89
97.84% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI40.37M0.36%11B USD0.35%$156.82-1.61%
iShares Russell 2000 ETFIWM26.15M0.03%77.55B USD0.19%$287.7-1.01%
Vanguard Morningstar Total Stock Market ETFVTI25.22M0.00%2.3T USD0.03%$373.24-0.62%
iShares Russell 2000 Growth ETFIWO9.67M0.07%14.32B USD0.24%$365.67-1.42%
Vanguard Extended Market ETFVXF9.27M0.01%93.7B USD0.05%$236.16-1.05%
iShares Biotechnology ETFIBB7.89M0.08%10.3B USD0.44%$202.64-1.39%
Fidelity Enhanced Small Cap ETFFESM6.1M0.09%6.49B USD0.28%$46.00-1.18%
Schwab U.S. Small-Cap ETFSCHA5.11M0.02%22.62B USD0.03%$33.65-1.32%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
